KPTI240816C2500
- 0.10
- 0.000.00%
Karyopharm Therapeutics Newsroom
Karyopharm Therapeutics Analyst Ratings
Karyopharm Therapeutics Analyst Ratings
Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)
Buy Rating for Karyopharm Therapeutics: Debt Restructuring and Promising Xpovio Studies Drive Optimistic Outlook
Karyopharm Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $8 Price Target
Optimistic Buy Rating for Karyopharm Therapeutics Amidst Financial Stability and Promising Clinical Trials
Karyopharm Therapeutics (KPTI) Gets a Buy From Barclays
Karyopharm Therapeutics (KPTI) Gets a Buy From Piper Sandler
Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Siemens Healthineers AG (OtherSEMHF)
Barclays Gives a Buy Rating to Karyopharm Therapeutics (KPTI)
RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)
Karyopharm Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: FibroGen (FGEN), Karyopharm Therapeutics (KPTI) and Day One Biopharmaceuticals (DAWN)
Piper Sandler Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)
Piper Sandler Reaffirms Their Buy Rating on Karyopharm Therapeutics (KPTI)
RBC Capital Keeps Their Buy Rating on Karyopharm Therapeutics (KPTI)
Hold Rating on Karyopharm Therapeutics: Evaluating Q3 Results, Impact of PAP and Prospects of Xpovio in Myelofibrosis Treatment
RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $3
Karyopharm Therapeutics Analyst Ratings